Resultados de la búsqueda - Portal de Modelos de Datos Médicos (MDM-Portal)

Filtrar resultados de búsqueda
Seleccionar modelos de datos

Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

4 Resultados de la búsqueda.

Eligibility Thrombosis Type 2 Diabetes NCT02373332

- 20/6/21 - 1 formulario, 2 itemgroups, 11 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Fatty Acid Regulation of Platelet Function in Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT02373332

Safety and Efficacy of Argatroban in Pediatric Patients, NCT00039858 - Eligibility Criteria

- 14/9/20 - 1 formulario, 3 itemgroups, 22 items, 1 idioma

Itemgroups: Administrative Data, Inclusion Criteria, Exclusion Criteria

Study ID: 105043/013 Clinical Study ID: 105043/013 Study Title: An Open-Label Study of Argatroban Injection to Evaluate the Safety and Effectiveness in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin (Protocol SKF105043/013) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00039858 Sponsor: GlaxoSmithKline Collaborators: Encysive Pharmaceuticals Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Argatroban Trade Name: N/A Study Indication: Thrombosis This Study evaluates the safety and the efficacy of i.v. Argatroban treatment in paediatric patients which require anticoagulants but aren't suitable for Heparin treatment. The study consists of screening visit (pre-treatment examination), treatment period of maximum 14 days after reaching therapeutical dose, post-treatment visit (once the treatment is stopped or after 14 days) and a follow-up visit which follows 30 days (+/- 14 days) after clinical resolution of underlying condition or after the end of the 14-day study period. Treatment can be continued after the 14-day study period if needed but such treatment isn't part of this Study. See https://clinicaltrials.gov/ct2/show/NCT00039858 The Eligibility Criteria Form has to be filled in at the screening visit. It determines the eligibility of the subject to participate in the study.

Eligibility Thrombosis NCT00447434

- 29/6/17 - 1 formulario, 2 itemgroups, 34 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Efficacy and Safety of Natto Extract; ODM derived from: https://clinicaltrials.gov/show/NCT00447434

Eligibility NCT00439725 Deep Vein Thrombosis - Eligibility

- 9/12/13 - 1 formulario, 3 itemgroups, 17 items, 2 idiomas

Itemgroups: Inclusion criteria, Exclusion criteria, Medical Concepts

This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT or PE who completed 6 or 12 months of treatment with rivaroxaban or VKA are eligible for this trial (Einstein-Extension study).

Utilice este formulario para comentarios, preguntas y sugerencias.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.